SERVICES,

                     Respondent.


           RESPONDENT’S PROFFER ON AWARD OF COMPENSATION

       On October 29, 2018, petitioner filed a petition seeking compensation under the

Vaccine Act for a shoulder injury related to vaccine administration (“SIRVA”) in her

upper left arm that she claimed occurred following an influenza (“flu”) vaccine

administered on October 15, 2016. On April 27, 2020, respondent conceded that

entitlement to compensation was appropriate under the terms of the Vaccine Act.

Thereafter, on April 28, 2020, the Chief Special Master issued a Ruling on Entitlement,

finding that petitioner was entitled to vaccine compensation under the Vaccine Act.

I.   with BPA, the infused compound was highly conjugated during passage through the liver, and the resultant metabolites were excreted from the liver. The main conjugate of the compound was mono-glucuronide. In male rats, approx. one-quarter of the infused BPA was eliminated as a glucuronide/sulfate diconjugate, whereas the diconjugate was virtually absent in female rats. These findings concur with a recent report, in which BPA, added to the medium of isolated hepatocytes, was metabolized into both mono-glucuronide and diconjugate; moreover, the diconjugate was almost nil in female rats \[[@r14]\]. BPA sulfo-conjugation is mediated by the SULT1 family, a phenol sulfotransferase isoform \[[@r17]\]. One member of the SULT1 family, SULT1A1, has been shown to have high-conjugation activity toward BPA \[[@r12]\]. The expression level of the SULT1 family is estimated to